Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$75.02 USD

75.02
1,449,518

+0.07 (0.09%)

Updated May 17, 2024 04:00 PM ET

After-Market: $75.00 -0.02 (-0.03%) 7:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Hologic (HOLX) Dips More Than Broader Markets: What You Should Know

Hologic (HOLX) closed the most recent trading day at $74.06, moving -1.41% from the previous trading session.

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Why Is Penumbra (PEN) Down 2.1% Since Last Earnings Report?

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic (HOLX) on the expanded global installed base of more than 3,250 Panthers instruments, representing the catalyst for sustained growth.

Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Hologic's (HOLX) Q3 Earnings Beat Estimates, 2023 View Up

Strength in Breast Health and GYN Surgical drives Hologic's (HOLX) Q3 performance.

Hologic (HOLX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Hologic (HOLX) Tops Q3 Earnings and Revenue Estimates

Hologic (HOLX) delivered earnings and revenue surprises of 5.68% and 2.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Alcon, Hologic and Penumbra

Alcon, Hologic and Penumbra have been highlighted in this Industry Outlook article.

Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Hologic (HOLX) closed at $81.32, marking a +0.54% move from the previous day.

Analysts Estimate Hologic (HOLX) to Report a Decline in Earnings: What to Look Out for

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

The Zacks Medical - Instruments industry is growing on rising demand for digital health. ALC, HOLX and PEN are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.

Breast Health Arm to Boost Hologic (HOLX) in Q3 Earnings

Hologic's (HOLX) Breast Health is likely to have driven Q3 performance, owing to strong performance from improved semiconductor chip availability and strong backlog.

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

The growing adoption of Panther instruments and an expanded Panther installed base as well as strength in Breast Health is expected to have driven Hologic's (HOLX) Q3 revenues.

QIAGEN (QGEN) Expands Digital PCR Offering With New Pact

QIAGEN (QGEN) and Niba Labs can assist companies developing cell and gene therapies to overcome significant resource limitations and adhere to stringent project deadlines.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

NextGen (NXGN) Settles Misrepresentation Allegations for $31M

NextGen (NXGN) settles accusations of software fraud and anti-kickback violations for $31M. However, the company denies any wrongdoing.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know

Hologic (HOLX) closed at $78.96 in the latest trading session, marking a -1.69% move from the prior day.

Boston Scientific (BSX) Gets FDA Nod for Vercise Software

Boston Scientific's (BSX) Vercise Neural Navigator 5 Software has an improved user interface that presents patient data in an easier-to-understand style and enables better therapy delivery.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) on strategic acquisitions and robust performance of the DSA and RMS arms.

Is AmerisourceBergen (ABC) Stock Outpacing Its Medical Peers This Year?

Here is how AmerisourceBergen (ABC) and Hologic (HOLX) have performed compared to their sector so far this year.